Israeli generic-drug giant Teva Pharmaceuticals had revenues of $3.55 billion in the third quarter of 2009. That's 25 percent more than in the same period in 2008, despite a $6 million loss caused by foreign exchange fluctuations. The revenues also came without any significant new product offerings.
The net profit of $806 million is 28 percent above the third-quarter figure for 2008.